Topical administration of Imiquimod, the ligand for TLR7, resolves skin manifestations in CLL patients and increased expression of co-stimulatory molecules on leukemic tumor cells [64]. The gene discussed is TLR7; the disease is B-cell chronic lymphocytic leukemia.